董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter Miles Davies | 男 | Independent Director | 45 | 6.87万美元 | 0.69 | 2026-09-18 |
| Alan Fisher | 男 | Independent Director | 73 | 12.89万美元 | 1.37 | 2026-09-18 |
| Jane Ryan | 女 | Independent Director | 67 | 6.87万美元 | 0.72 | 2026-09-18 |
| David Wilson | 男 | Director | 63 | 7.31万美元 | 0.70 | 2026-09-18 |
| Spyridon Papapetropoulos | 男 | Director and Interim Chief Executive Officer | 53 | 167.47万美元 | 4.93 | 2026-09-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Spyridon Papapetropoulos | 男 | Director and Interim Chief Executive Officer | 53 | 167.47万美元 | 4.93 | 2026-09-18 |
董事简历
中英对照 | 中文 | 英文- Peter Miles Davies
-
Peter Miles Davies自2021年7月起担任公司董事会成员，自2024年6月17日起生效，获委任为公司审核委员会成员。戴维斯先生于2021年至2022年在Apeiron Investment Group Ltd的医疗团队工作。在此之前，戴维斯先生曾于2006年至2021年在Rothschild & Co.任职。戴维斯先生获得了苏格兰爱丁堡大学的硕士学位。戴维斯先生在医疗保健行业的经验包括并购、战略咨询、融资和重组交易，这些都有助于董事会得出结论，即他应该担任公司董事。
Peter Miles Davies has served as a member of the company's board of directors since July 2021, and effective June 17, 2024, was appointed as a member of the company's Audit Committee. Mr. Davies has worked at Apeiron Investment Group Ltd in the Healthcare team from 2021 to 2022. Prior to that, Mr. Davies was at Rothschild & Co. from 2006 to 2021. Mr. Davies received his Master's Degree from The University of Edinburgh, Scotland. Mr. Davies' experience in the healthcare industry includes mergers and acquisitions, strategic advisory, capital raising, and restructuring transactions, which all contributed to board of directors' conclusion that he should serve as a director of company. - Peter Miles Davies自2021年7月起担任公司董事会成员，自2024年6月17日起生效，获委任为公司审核委员会成员。戴维斯先生于2021年至2022年在Apeiron Investment Group Ltd的医疗团队工作。在此之前，戴维斯先生曾于2006年至2021年在Rothschild & Co.任职。戴维斯先生获得了苏格兰爱丁堡大学的硕士学位。戴维斯先生在医疗保健行业的经验包括并购、战略咨询、融资和重组交易，这些都有助于董事会得出结论，即他应该担任公司董事。
- Peter Miles Davies has served as a member of the company's board of directors since July 2021, and effective June 17, 2024, was appointed as a member of the company's Audit Committee. Mr. Davies has worked at Apeiron Investment Group Ltd in the Healthcare team from 2021 to 2022. Prior to that, Mr. Davies was at Rothschild & Co. from 2006 to 2021. Mr. Davies received his Master's Degree from The University of Edinburgh, Scotland. Mr. Davies' experience in the healthcare industry includes mergers and acquisitions, strategic advisory, capital raising, and restructuring transactions, which all contributed to board of directors' conclusion that he should serve as a director of company.
- Alan Fisher
-
自2016年9月1日起担任董事会成员的Alan Fisher被任命为董事会非执行主席，自2023年7月1日起生效。他也是审计和风险管理委员会主席以及提名和薪酬委员会成员。Fisher先生自1997年以来一直担任Fisher Corporate Advisory Pty Ltd.的董事总经理，在该公司为上市公司和私营公司提供并购、公共和私募股权融资、业务重组和战略建议方面的建议。他目前在ASX上市公司Thorney Technologies Limited（非执行董事–审计和风险管理委员会主席）的董事会任职，该公司是一家投资公司，自2014年起任职。Fisher先生于1974年至1997年在Coopers & Lybrand工作，并于1985年至1997年担任公司财务合伙人。Fisher先生在澳大利亚墨尔本大学获得会计学学士学位，是澳大利亚和新西兰特许会计师协会的研究员。
Alan Fisher a member of the Board since September 1, 2016, was appointed Non Executive Chair of the Board, effective from July 1, 2023. He is also Chair of the Audit and Risk Management Committee and a member of the Nomination and Compensation Committee. Mr. Fisher has served as the Managing Director of Fisher Corporate Advisory Pty Ltd. since 1997, where he advises public and private companies on mergers and acquisitions, public and private equity raisings, business restructuring and strategic advice. He currently serves on the board of ASX listed company Thorney Technologies Limited (Non Executive Director – Chair of Audit and Risk Management Committee), an investment company, since 2014. Mr. Fisher worked at Coopers & Lybrand from 1974 to 1997, and served as a Corporate Finance Partner from 1985 1997. Mr. Fisher received his B.Com., Accounting from the University of Melbourne, Australia and is a Fellow of the Australian and New Zealand Institute of Chartered Accountants. - 自2016年9月1日起担任董事会成员的Alan Fisher被任命为董事会非执行主席，自2023年7月1日起生效。他也是审计和风险管理委员会主席以及提名和薪酬委员会成员。Fisher先生自1997年以来一直担任Fisher Corporate Advisory Pty Ltd.的董事总经理，在该公司为上市公司和私营公司提供并购、公共和私募股权融资、业务重组和战略建议方面的建议。他目前在ASX上市公司Thorney Technologies Limited（非执行董事–审计和风险管理委员会主席）的董事会任职，该公司是一家投资公司，自2014年起任职。Fisher先生于1974年至1997年在Coopers & Lybrand工作，并于1985年至1997年担任公司财务合伙人。Fisher先生在澳大利亚墨尔本大学获得会计学学士学位，是澳大利亚和新西兰特许会计师协会的研究员。
- Alan Fisher a member of the Board since September 1, 2016, was appointed Non Executive Chair of the Board, effective from July 1, 2023. He is also Chair of the Audit and Risk Management Committee and a member of the Nomination and Compensation Committee. Mr. Fisher has served as the Managing Director of Fisher Corporate Advisory Pty Ltd. since 1997, where he advises public and private companies on mergers and acquisitions, public and private equity raisings, business restructuring and strategic advice. He currently serves on the board of ASX listed company Thorney Technologies Limited (Non Executive Director – Chair of Audit and Risk Management Committee), an investment company, since 2014. Mr. Fisher worked at Coopers & Lybrand from 1974 to 1997, and served as a Corporate Finance Partner from 1985 1997. Mr. Fisher received his B.Com., Accounting from the University of Melbourne, Australia and is a Fellow of the Australian and New Zealand Institute of Chartered Accountants.
- Jane Ryan
-
Jane Ryan自2020年10月起担任公司董事会成员。Ryan博士是审计和风险管理委员会的成员，也是提名和薪酬委员会的主席。自2014年1月起，Dr. Ryan在资本筹集、业务发展和并购方面为生物技术公司提供高管级咨询服务。Ryan博士目前担任Viral Vector Manufacturing Facility Pty Ltd.的非执行董事。她此前曾担任BCAL Diagnostics的商业和产品开发顾问，BCAL Diagnostics是一家在ASX上市的癌症诊断公司。从2014年到2017年，Ryan博士担任Sementis Ltd.的首席执行官，该公司是一家开发疫苗技术的上市公司（未上市）。在此之前，Ryan博士是Biota的高管和产品开发部门负责人，Biota是一家在ASX和纳斯达克上市的生物技术公司，在那里她负责监督Biota的开发组合和计划，包括与美国政府谈判并赢得2.31亿美元的先进开发合同。2018年至2023年，Ryan博士担任ASX上市公司Anatara Life Sciences的董事。瑞安博士自2022年1月起担任上市公司IDT Australia Limited董事。她还是澳大利亚公司董事协会的成员。她在澳大利亚国立大学获得理学学士学位，在麦格理大学获得博士学位，并且是哥伦比亚大学的博士后研究员。
Jane Ryan has served as a member of the company's board of directors since October 2020. Dr. Ryan is a member of the Audit and Risk Management Committee and Chair of the Nomination and Compensation Committee. Since January 2014, Dr. Ryan has provided executive level advisory services to biotechnology companies in connection with capital raising, business development, and mergers and acquisitions. Dr. Ryan currently serves as a non executive director of Viral Vector Manufacturing Facility Pty Ltd. She previously served as commercial and product development advisor to BCAL Diagnostics, a cancer diagnostics company listed on the ASX. From 2014 to 2017, Dr. Ryan served as the CEO of Sementis Ltd., a public company (unlisted) developing vaccine technology. Prior to that, Dr. Ryan was an executive and division leader of product development at Biota, a biotechnology company listed on the ASX and Nasdaq, where she provided oversight to Biota's development portfolio and programs, including the negotiation and winning of a $231 million advanced development contract with the government of the United States. From 2018 to 2023, Dr. Ryan served as director of Anatara Life Sciences, an ASX listed company. Dr. Ryan has served as a director of IDT Australia Limited since January 2022, a listed company. She is also a member of the Australian Institute of Company Directors. She received her B.Sc. from the Australia National University, her Ph.D. from Macquarie University and was a Postdoctoral Fellow at Columbia University. - Jane Ryan自2020年10月起担任公司董事会成员。Ryan博士是审计和风险管理委员会的成员，也是提名和薪酬委员会的主席。自2014年1月起，Dr. Ryan在资本筹集、业务发展和并购方面为生物技术公司提供高管级咨询服务。Ryan博士目前担任Viral Vector Manufacturing Facility Pty Ltd.的非执行董事。她此前曾担任BCAL Diagnostics的商业和产品开发顾问，BCAL Diagnostics是一家在ASX上市的癌症诊断公司。从2014年到2017年，Ryan博士担任Sementis Ltd.的首席执行官，该公司是一家开发疫苗技术的上市公司（未上市）。在此之前，Ryan博士是Biota的高管和产品开发部门负责人，Biota是一家在ASX和纳斯达克上市的生物技术公司，在那里她负责监督Biota的开发组合和计划，包括与美国政府谈判并赢得2.31亿美元的先进开发合同。2018年至2023年，Ryan博士担任ASX上市公司Anatara Life Sciences的董事。瑞安博士自2022年1月起担任上市公司IDT Australia Limited董事。她还是澳大利亚公司董事协会的成员。她在澳大利亚国立大学获得理学学士学位，在麦格理大学获得博士学位，并且是哥伦比亚大学的博士后研究员。
- Jane Ryan has served as a member of the company's board of directors since October 2020. Dr. Ryan is a member of the Audit and Risk Management Committee and Chair of the Nomination and Compensation Committee. Since January 2014, Dr. Ryan has provided executive level advisory services to biotechnology companies in connection with capital raising, business development, and mergers and acquisitions. Dr. Ryan currently serves as a non executive director of Viral Vector Manufacturing Facility Pty Ltd. She previously served as commercial and product development advisor to BCAL Diagnostics, a cancer diagnostics company listed on the ASX. From 2014 to 2017, Dr. Ryan served as the CEO of Sementis Ltd., a public company (unlisted) developing vaccine technology. Prior to that, Dr. Ryan was an executive and division leader of product development at Biota, a biotechnology company listed on the ASX and Nasdaq, where she provided oversight to Biota's development portfolio and programs, including the negotiation and winning of a $231 million advanced development contract with the government of the United States. From 2018 to 2023, Dr. Ryan served as director of Anatara Life Sciences, an ASX listed company. Dr. Ryan has served as a director of IDT Australia Limited since January 2022, a listed company. She is also a member of the Australian Institute of Company Directors. She received her B.Sc. from the Australia National University, her Ph.D. from Macquarie University and was a Postdoctoral Fellow at Columbia University.
- David Wilson
-
David Wilson自2016年6月起担任公司董事会成员。自2011年11月起，他担任WG Partners LLP的董事长和创始合伙人，WG Partners LLP是一家投资银行精品，为生命科学公司提供企业融资、并购和融资方面的建议。在加入WG Partners LLP之前，Wilson先生曾于2001年至2011年在Piper Jaffray担任过各种职务，包括欧洲业务首席执行官、全球医疗保健团队主席和全球运营委员会成员。他还曾于1999年至2001年担任ING投资银行业务董事总经理，并于1998年至1999年担任德意志银行小公司企业融资主管。自2021年7月以来，他目前担任多家私营公司的董事会成员，其中包括总部位于英国的制药公司CS Pharmaceuticals Limited。Wilson先生获得了剑桥大学的学士学位。Wilson先生在医疗保健行业的企业融资和资本筹集方面的经验促成了公司董事会的结论，即他应该担任公司公司的董事。
David Wilson has served as a member of the company's board of directors since June 2016. He has served as the Chairman and founding partner of WG Partners LLP, an investment banking boutique advising life sciences companies on corporate finance, mergers and acquisitions, and capital raising, since November 2011. Prior to WG Partners LLP, Mr. Wilson worked at Piper Jaffray in various roles from 2001 to 2011, including CEO of European Operations, Chairman of the Global Healthcare Team and a Member of the Global Operating Board. He was also a Managing Director of ING Investment Banking from 1999 to 2001 and the Head of Small Companies Corporate Finance at Deutsche Bank from 1998 to 1999. He is currently on the board of directors of several privately held companies, including CS Pharmaceuticals Limited, a pharmaceutical company based in the United Kingdom, since July 2021. Mr. Wilson received his Bachelor's degree from the University of Cambridge. Mr. Wilson's experience in corporate finance and capital raising in the healthcare industry contributed to the company's board of directors' conclusion that he should serve as a director of the company's company. - David Wilson自2016年6月起担任公司董事会成员。自2011年11月起，他担任WG Partners LLP的董事长和创始合伙人，WG Partners LLP是一家投资银行精品，为生命科学公司提供企业融资、并购和融资方面的建议。在加入WG Partners LLP之前，Wilson先生曾于2001年至2011年在Piper Jaffray担任过各种职务，包括欧洲业务首席执行官、全球医疗保健团队主席和全球运营委员会成员。他还曾于1999年至2001年担任ING投资银行业务董事总经理，并于1998年至1999年担任德意志银行小公司企业融资主管。自2021年7月以来，他目前担任多家私营公司的董事会成员，其中包括总部位于英国的制药公司CS Pharmaceuticals Limited。Wilson先生获得了剑桥大学的学士学位。Wilson先生在医疗保健行业的企业融资和资本筹集方面的经验促成了公司董事会的结论，即他应该担任公司公司的董事。
- David Wilson has served as a member of the company's board of directors since June 2016. He has served as the Chairman and founding partner of WG Partners LLP, an investment banking boutique advising life sciences companies on corporate finance, mergers and acquisitions, and capital raising, since November 2011. Prior to WG Partners LLP, Mr. Wilson worked at Piper Jaffray in various roles from 2001 to 2011, including CEO of European Operations, Chairman of the Global Healthcare Team and a Member of the Global Operating Board. He was also a Managing Director of ING Investment Banking from 1999 to 2001 and the Head of Small Companies Corporate Finance at Deutsche Bank from 1998 to 1999. He is currently on the board of directors of several privately held companies, including CS Pharmaceuticals Limited, a pharmaceutical company based in the United Kingdom, since July 2021. Mr. Wilson received his Bachelor's degree from the University of Cambridge. Mr. Wilson's experience in corporate finance and capital raising in the healthcare industry contributed to the company's board of directors' conclusion that he should serve as a director of the company's company.
- Spyridon Papapetropoulos
-
Spyridon Papapetropoulos自2023年1月5日起担任公司总裁兼首席执行官，自2026年1月1日起担任临时首席执行官。Papapetropoulos博士是一位经验丰富的生物制药高管，是一位公认的神经科学家/神经学家，也是一位拥有26年专注于中枢神经系统疾病的职业生涯的变革推动者。他曾在CNS专注的初创/中小型专业和大型生物制药公司担任过越来越多的职务。2020年至今，他担任Vigil Neuroscience Inc的首席医疗官，该公司是一家在纳斯达克上市的生物制药公司，开发用于治疗神经退行性疾病的神经免疫靶向疗法的管道。在加入Vigil之前，他曾担任首席开发官、高级副总裁、Acadia Pharmaceuticals Inc.开发主管、SwanBio Therapeutics首席执行官、Cavion研发执行副总裁兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、艾尔建（Allergan）公司、辉瑞公司（TERM1）和梯瓦制药（Teva Pharmaceuticals Inc）担任高级/高管职务。Papapetropoulos博士已申请了多个IND，并监督了广泛的CNS生物制药开发项目（小分子、生物制剂、基因治疗），导致成功的监管申报（> 20个IND和多个NDAs/BLA）和全球新产品发布。Papapetropoulos博士在希腊的帕特雷大学医学院获得医学博士和博士学位，在加入生物制药行业之前，曾在迈阿密大学医学院神经病学系担任教员。
Spyridon Papapetropoulos has served as the company's President and Chief Executive Officer since January 5, 2023, and as the Interim Chief Executive Officer since January 1, 2026. Dr. Papapetropoulos is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 26 year career focused on CNS disorders. He has held various positions of increasing responsibility at CNS focused start up/small, medium specialty and large biopharma companies. Since 2020, he was the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Dr. Papapetropoulos received his MD and PhD in Greece from the University of Patras, School of Medicine and before joining the biopharmaceutical industry served as faculty at the Department of Neurology of the University of Miami, School of Medicine. - Spyridon Papapetropoulos自2023年1月5日起担任公司总裁兼首席执行官，自2026年1月1日起担任临时首席执行官。Papapetropoulos博士是一位经验丰富的生物制药高管，是一位公认的神经科学家/神经学家，也是一位拥有26年专注于中枢神经系统疾病的职业生涯的变革推动者。他曾在CNS专注的初创/中小型专业和大型生物制药公司担任过越来越多的职务。2020年至今，他担任Vigil Neuroscience Inc的首席医疗官，该公司是一家在纳斯达克上市的生物制药公司，开发用于治疗神经退行性疾病的神经免疫靶向疗法的管道。在加入Vigil之前，他曾担任首席开发官、高级副总裁、Acadia Pharmaceuticals Inc.开发主管、SwanBio Therapeutics首席执行官、Cavion研发执行副总裁兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、艾尔建（Allergan）公司、辉瑞公司（TERM1）和梯瓦制药（Teva Pharmaceuticals Inc）担任高级/高管职务。Papapetropoulos博士已申请了多个IND，并监督了广泛的CNS生物制药开发项目（小分子、生物制剂、基因治疗），导致成功的监管申报（> 20个IND和多个NDAs/BLA）和全球新产品发布。Papapetropoulos博士在希腊的帕特雷大学医学院获得医学博士和博士学位，在加入生物制药行业之前，曾在迈阿密大学医学院神经病学系担任教员。
- Spyridon Papapetropoulos has served as the company's President and Chief Executive Officer since January 5, 2023, and as the Interim Chief Executive Officer since January 1, 2026. Dr. Papapetropoulos is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 26 year career focused on CNS disorders. He has held various positions of increasing responsibility at CNS focused start up/small, medium specialty and large biopharma companies. Since 2020, he was the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Dr. Papapetropoulos received his MD and PhD in Greece from the University of Patras, School of Medicine and before joining the biopharmaceutical industry served as faculty at the Department of Neurology of the University of Miami, School of Medicine.
高管简历
中英对照 | 中文 | 英文- Spyridon Papapetropoulos
Spyridon Papapetropoulos自2023年1月5日起担任公司总裁兼首席执行官，自2026年1月1日起担任临时首席执行官。Papapetropoulos博士是一位经验丰富的生物制药高管，是一位公认的神经科学家/神经学家，也是一位拥有26年专注于中枢神经系统疾病的职业生涯的变革推动者。他曾在CNS专注的初创/中小型专业和大型生物制药公司担任过越来越多的职务。2020年至今，他担任Vigil Neuroscience Inc的首席医疗官，该公司是一家在纳斯达克上市的生物制药公司，开发用于治疗神经退行性疾病的神经免疫靶向疗法的管道。在加入Vigil之前，他曾担任首席开发官、高级副总裁、Acadia Pharmaceuticals Inc.开发主管、SwanBio Therapeutics首席执行官、Cavion研发执行副总裁兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、艾尔建（Allergan）公司、辉瑞公司（TERM1）和梯瓦制药（Teva Pharmaceuticals Inc）担任高级/高管职务。Papapetropoulos博士已申请了多个IND，并监督了广泛的CNS生物制药开发项目（小分子、生物制剂、基因治疗），导致成功的监管申报（> 20个IND和多个NDAs/BLA）和全球新产品发布。Papapetropoulos博士在希腊的帕特雷大学医学院获得医学博士和博士学位，在加入生物制药行业之前，曾在迈阿密大学医学院神经病学系担任教员。
Spyridon Papapetropoulos has served as the company's President and Chief Executive Officer since January 5, 2023, and as the Interim Chief Executive Officer since January 1, 2026. Dr. Papapetropoulos is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 26 year career focused on CNS disorders. He has held various positions of increasing responsibility at CNS focused start up/small, medium specialty and large biopharma companies. Since 2020, he was the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Dr. Papapetropoulos received his MD and PhD in Greece from the University of Patras, School of Medicine and before joining the biopharmaceutical industry served as faculty at the Department of Neurology of the University of Miami, School of Medicine.- Spyridon Papapetropoulos自2023年1月5日起担任公司总裁兼首席执行官，自2026年1月1日起担任临时首席执行官。Papapetropoulos博士是一位经验丰富的生物制药高管，是一位公认的神经科学家/神经学家，也是一位拥有26年专注于中枢神经系统疾病的职业生涯的变革推动者。他曾在CNS专注的初创/中小型专业和大型生物制药公司担任过越来越多的职务。2020年至今，他担任Vigil Neuroscience Inc的首席医疗官，该公司是一家在纳斯达克上市的生物制药公司，开发用于治疗神经退行性疾病的神经免疫靶向疗法的管道。在加入Vigil之前，他曾担任首席开发官、高级副总裁、Acadia Pharmaceuticals Inc.开发主管、SwanBio Therapeutics首席执行官、Cavion研发执行副总裁兼首席医疗官。在加入Cavion之前，他曾在Biogen Inc.、艾尔建（Allergan）公司、辉瑞公司（TERM1）和梯瓦制药（Teva Pharmaceuticals Inc）担任高级/高管职务。Papapetropoulos博士已申请了多个IND，并监督了广泛的CNS生物制药开发项目（小分子、生物制剂、基因治疗），导致成功的监管申报（> 20个IND和多个NDAs/BLA）和全球新产品发布。Papapetropoulos博士在希腊的帕特雷大学医学院获得医学博士和博士学位，在加入生物制药行业之前，曾在迈阿密大学医学院神经病学系担任教员。
- Spyridon Papapetropoulos has served as the company's President and Chief Executive Officer since January 5, 2023, and as the Interim Chief Executive Officer since January 1, 2026. Dr. Papapetropoulos is an experienced biopharmaceutical executive, a recognized neuroscientist/neurologist, and change agent with a 26 year career focused on CNS disorders. He has held various positions of increasing responsibility at CNS focused start up/small, medium specialty and large biopharma companies. Since 2020, he was the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Prior to joining Vigil, he served as Chief Development Officer, and SVP, Head of Development at Acadia Pharmaceuticals Inc., CEO at SwanBio Therapeutics, and EVP of Research & Development and Chief Medical Officer at Cavion. Before Cavion, he held senior/executive positions at Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. Dr. Papapetropoulos has filed multiple INDs and has overseen a broad spectrum of CNS biopharmaceutical development programs (small molecules, biologics, gene therapy), leading to successful regulatory filings (>20 INDs and multiple NDAs/BLAs) and new product launches worldwide. Dr. Papapetropoulos received his MD and PhD in Greece from the University of Patras, School of Medicine and before joining the biopharmaceutical industry served as faculty at the Department of Neurology of the University of Miami, School of Medicine.